Sewon Yi
About Sewon Yi
Sewon Yi is the Strategic & New Product Marketing Manager at Bristol-Myers Squibb Korea, specializing in oncology and hepatitis C treatments.
Current Position at Bristol-Myers Squibb Korea
Sewon Yi holds the position of Strategic & New Product Marketing Manager at Bristol-Myers Squibb Korea. In this role, Sewon Yi is responsible for developing and implementing marketing strategies for new and existing products. Since joining the company in March 2012, Sewon Yi has focused on marketing efforts for critical pharmaceutical products targeted at serious health conditions, particularly in the field of oncology and hepatitis.
Educational Background
Sewon Yi has a rich educational background with studies completed at two prestigious institutions in South Korea. Sewon Yi attended Ewha Womans University, which is known for its rigorous academic programs. Additionally, Sewon Yi pursued further education at Korea University, one of the leading universities in the country. This educational foundation has equipped Sewon Yi with the knowledge and skills necessary for a career in strategic marketing within the pharmaceutical industry.
Experience with Oncology Product Marketing
Sewon Yi manages marketing strategies specifically for oncology products at Bristol-Myers Squibb Korea. One of the key products handled is brivanib, which is aimed at treating hepatocellular carcinoma (HCC). Additionally, Sewon Yi oversees the immuno-oncology marketing efforts for products such as Yervoy, which is used in the treatment of melanoma and lung cancer. Through these responsibilities, Sewon Yi plays a crucial role in the promotion and market penetration of life-saving oncology treatments.
Role in Hepatitis C Treatment Marketing
In addition to oncology products, Sewon Yi is responsible for the marketing of hepatitis C treatments at Bristol-Myers Squibb Korea. A significant product in this category is Daklinza, a medication used in the treatment of hepatitis C. Sewon Yi's role includes creating and executing marketing strategies to ensure the product's successful adoption in the medical community and its availability to patients in need. This work is integral to the company’s mission of delivering innovative therapies to improve patient outcomes.